In the present study, we formulated the HALOA complex from human alpha-lactalbumin with oleic acid by direct mixing, which has the therapeutic capability to target different paradigms of chronic myeloid leukemia (CML), which are responsible for proliferation to angiogenesis. The gene discussed is LALBA; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.